Consolidated EBITDA rose 29.6% to Rs 303 crore in Q4 March 2020, from Rs 2,33.80 crore in Q4 March 2019. EBITDA margin improved to 14.8% in Q4 March 2020 from 12.6% in Q4 March 2019.
During the quarter, India sales stood at Rs 1,257.60 crore (up 3.3%) and International sales stood at Rs 752.30 crore (up 23.4%).
Alkem Laboratories said R&D expenses for the quarter ending March 2020 was at Rs 125.30 crore or 6.1% of revenue from operations compared with Rs 139.20 crore at 7.5% of revenue from operations in Q4 March 2019.
Commenting on the results, Sandeep Singh, managing director, Alkem said, Adjusting for the impact of delay in transportation due to lockdown which led to a lower booking of sales in the month of March 2020, our India business delivered a healthy double digit growth during the quarter and the year. Our US business also complimented well with a robust growth on the back of new product launches and market share gains. The company's EBITDA margins improved by more than 200 bps during the quarter and the year, thereby highlighting our ongoing efforts towards cost optimization and process improvement. While FY21 has started on a challenging note due to COVID-19, we are positive that the inherent business strengths that we have built over the years in terms of strong brands, marketing and distribution infrastructure and H&U investments, will help us to navigate through these testing times and deliver a sustainable and a profitable growth.
The board recommended a dividend of Rs 3 per equity share and fixed 11 August 2020 as a record date.
Alkem Laboratories is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products. The company operates through two segments: pharmaceutical and investing.
Shares of Alkem Laboratories fell 1.92% to Rs 2395.95 on Friday. Meanwhile the S&P BSE Sensex closed 306.54 points or 0.9% higher at 34,287.24.
Powered by Capital Market - Live News
Beware of fraudulent tips, unauthenticated news and advice on stock market.
At BOB Capital, your account security is our topmost priority. Beware of receiving fraudulent communications, unauthenticated trading tips and unsolicited calls on trading in stocks from unverified sources, received through Whatsapp, Telegram, SMS, Calls, etc and take an informed decision before investing.
What should you do if you receive a trading tip over phone or SMS?
Report unsolicited messages to the Stock Exchange on +91 8291833676 or on designated email id i.e. feedbk_invg@nse.co.in. Please visit here to understand better.
Valued Customer,
BOB Capital Markets Limited (BOBCaps) is firmly committed to the safety of your wealth. We would like to bring to your notice certain precautions that you certainly must take against potential tele-fraudsters/ unscrupulous and unregistered portfolio managers:
ALWAYS AVOID
Certain tele-fraudsters / unscrupulous and unregistered portfolio managers call customers or SMS them on the pretext of providing investment tips and lure them to invest through their bogus firms by promising huge profits. Such deceitful callers ask the customer to share his/her login credentials with passwords to allow trading in their accounts, assuring huge returns. Often trades done in the customer’s accounts are far from the best interest of the customers. Holdings of customers are often sold and with the funds, trades are then placed in illiquid securities at unrealistic prices. At times, the holdings of customers are sold at prices detrimental to the customer.
The so-called “portfolio manager” assures profits, which naturally does not materialize. Customers are deceived into providing access to their trading accounts, thereby allowing such fraudsters access to funds and securities available to execute trades, injurious to the customer’s interest.
We would like to caution you against such fraudulent calls and SMSes and urge you to be alert. Follow the golden rule:
Do not share your Login Credentials or Passwords with anybody
BOBCaps employees / representatives never ask for your password.
The following illicit activities by the persons named herein have come to the notice of Stock Exchanges: